Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
CRISPR/CasRx suppresses KRAS-induced brain arteriovenous malformation developed in postnatal brain endothelial cells in mice
Shoji Saito, Yuka Nakamura, Satoshi Miyashita, Tokiharu Sato, Kana Hoshina, Masayasu Okada, Hitoshi Hasegawa, Makoto Oishi, Yukihiko Fujii, Jakob Körbelin, Yoshiaki Kubota, Kazuki Tainaka, Manabu Natsumeda, Masaki Ueno
Shoji Saito, Yuka Nakamura, Satoshi Miyashita, Tokiharu Sato, Kana Hoshina, Masayasu Okada, Hitoshi Hasegawa, Makoto Oishi, Yukihiko Fujii, Jakob Körbelin, Yoshiaki Kubota, Kazuki Tainaka, Manabu Natsumeda, Masaki Ueno
View: Text | PDF
Research Article Neuroscience

CRISPR/CasRx suppresses KRAS-induced brain arteriovenous malformation developed in postnatal brain endothelial cells in mice

  • Text
  • PDF
Abstract

Brain arteriovenous malformations (bAVMs) are anomalies forming vascular tangles connecting the arteries and veins, which cause hemorrhagic stroke in young adults. Current surgical approaches are highly invasive, and alternative therapeutic methods are warranted. Recent genetic studies identified KRAS mutations in endothelial cells of bAVMs; however, the underlying process leading to malformation in the postnatal stage remains unknown. Here we established a mouse model of bAVM developing during the early postnatal stage. Among 4 methods tested, mutant KRAS specifically introduced in brain endothelial cells by brain endothelial cell–directed adeno-associated virus (AAV) and endothelial cell–specific Cdh5-CreERT2 mice successfully induced bAVMs in the postnatal period. Mutant KRAS led to the development of multiple vascular tangles and hemorrhage in the brain with increased MAPK/ERK signaling and growth in endothelial cells. Three-dimensional analyses in cleared tissue revealed dilated vascular networks connecting arteries and veins, similar to human bAVMs. Single-cell RNA-Seq revealed dysregulated gene expressions in endothelial cells and multiple cell types involved in the pathological process. Finally, we employed CRISPR/CasRx to knock down mutant KRAS expression, which efficiently suppressed bAVM development. The present model reveals pathological processes that lead to postnatal bAVMs and demonstrates the efficacy of therapeutic strategies with CRISPR/CasRx.

Authors

Shoji Saito, Yuka Nakamura, Satoshi Miyashita, Tokiharu Sato, Kana Hoshina, Masayasu Okada, Hitoshi Hasegawa, Makoto Oishi, Yukihiko Fujii, Jakob Körbelin, Yoshiaki Kubota, Kazuki Tainaka, Manabu Natsumeda, Masaki Ueno

×

Figure 7

KRAS knockdown by AAV delivery of CRISPR/CasRx suppressed bAVM development.

Options: View larger image (or click on image) Download as PowerPoint

KRAS knockdown by AAV delivery of CRISPR/CasRx suppressed bAVM developm...
(A) A design of CRISPR/CasRx to silence KRASG12D mRNA expression. DR, direct repeat. The right bottom image was modified from refs. 45, 47. (B) KRAS mRNA expressions in HEK293T cells transfected with control, KRASG12D, and KRASG12D-targeting CRISPR/CasRx plasmids in real-time PCR. n = 3, 1-way ANOVA followed by Tukey’s test. (C) Survival curves of KRASG12D-induced (1 × 109 GC) and KRASG12D-CasRx–treated (1 × 1010 GC) mice. n = 13 and 10, log-rank test. (D) Brain images of KRASG12D-induced (1 × 109 GC) and CasRx-treated mice at P21. (E and F) Representative images of vascular tangle formation (arrowheads) in KRASG12D-induced (1 × 109 GC, E) and CasRx-treated (F) mice. (G and H) Lesion numbers (G) and size (H) in KRASG12D-induced (1 × 109 GC) and CasRx-treated mice. n = 4, unpaired t test (G), 2-way repeated ANOVA followed by Bonferroni’s test (H). (I) Percentage of mice forming lesions in KRASG12D-induced (1 × 109 GC, n = 13; 3 × 107 GC, n = 10) and CasRx-treated mice (n = 10, 8, 7). (J–O) P42 brains of KRASG12D-induced (3 × 107 GC, J and K) and CasRx-treated mice (L and M, treated at P5; N and O, treated at P19). Bottom panels (K, M, and O) show histological images of vascular tangles in the upper panels (arrowheads, J and N) or corresponding areas (M). (P and Q) Lesion numbers (P) and size (Q) in KRASG12D-induced (3 × 107 GC) and CasRx-treated mice. n = 10, 8, 7, Kruskal-Wallis test followed by Dunn’s multiple-comparison test (P); n = 5, 4, Mann Whitney U test (Q). ***P < 0.001, **P < 0.01, *P < 0.05. Scale bars: 2 mm (D, J, L, and N), 500 μm (E and F), 200 μm (K, M, and O).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts